Contribution of Anti-Platelet Antibodies Identified with MAIPA Assess in the Demonstration of the Autoimmune Character of a Thrombocytopenia at Diagnosis (APAT)

This single center experimental study is based out of University Hospital in Bordeaux, France and is designed to assess the contribution of anti-platelet antibodies identified with monoclonal antibody immobilization of platelet antigens (MAIPA) to determine the autoimmune nature of a thrombocytopenia at diagnosis. The gold standard analysis for the determination of platelet antibodies, is the MAIPA assay. This trial is open to adults over the age of 18 years who have never been treated for their ITP and who have a platelet count less than 100 µL.



back to top

Charity NavigatorGuideStar Seal NORD Member BadgeTHSNA logo